MedWatch·Financial report·Business & finance·4w agoNordea raises Demant price target on strong US demand for Oticon ZealSustained US demand for the Oticon Zeal suggests the premium hearing aid segment remains robust, which may influence clinic purchasing decisions and manufacturer investment in product development.
MedWatch·Financial report·Business & finance·3mo agoPositive outlook at Demant prompts Nordea to raise its price targetDemant's strong financial outlook signals continued investment capacity in hearing aid innovation, which may influence product pipelines and market competition for clinics and dispensers.＋Save
